Evommune

Check out CURE article on Evommune's goal in developing new and improved treatment options for patients living with chronic inflammatory diseases. #inflammation #inflammatorydiseases #biotechnology https://lnkd.in/gNpdSaHG

Check out CURE article on Evommune's goal in developing new and improved treatment options for patients living with chronic inflammatory diseases. #inflammation #inflammatorydiseases #biotechnology https://lnkd.in/gNpdSaHG

Evommune wishes to congratulate Eli Lilly on obtaining FDA approval for Ebglyss™ (lebrikizumab-ibkz). Several of our current Evommune colleagues played a role in its development, and are proud of its approval. Our drive to continue to deliver meaningful new medicines to patients has never been stronger. Chronic inflammation destroys lives and Evommune is here to do something about it! https://lnkd.in/gzKkPXi7

All of us at Evommune are deeply saddened by the recent passing of Dr. Marcus Maurer, a scientific collaborator at the Institute of Allergology at Charité in Berlin. #dermatology #inflammation #immunology

Evommune will be presenting a corporate update, including this week’s news on the commencement of a Phase 2 trial in adult patients with chronic inducible urticaria, at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City. Presentation will take place on Thursday, September 5th at the Marriott Marquis.

Dermatology Times article on our Phase 2 trial in Chronic Inducible Urticaria. https://lnkd.in/gJHp65QE

Evommune continues executing on its clinical development plans: Commencing a Phase 2 trial in 15 study sites across the United States, we have now enrolled the first patient in a study evaluating EVO756 in adults with chronic inducible urticaria. EVO756 is a potent, highly selective small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2) and represents a new, targeted approach to mast-cell mediated diseases with the potential for once-daily oral administration without the serious side effects observed with other therapies. https://lnkd.in/gx84qTfP https://lnkd.in/gx84qTfP

Evommune pipeline update: Data from a proof-of-concept trial with our MRGPRX2 antagonist (EVO756) exceeded our expectations, and we now plan to initiate multiple clinical trials, including a Phase 2b study in chronic spontaneous urticaria patients during the first half of 2025. We believe EVO756 is a potential treatment option for patients suffering from various mast-cell mediated diseases. https://lnkd.in/gzUGPVdq

Evommune pipeline update: Data from a proof-of-concept trial with our MRGPRX2 antagonist (EVO756) exceeded our expectations, and we now plan to initiate multiple clinical trials, including a Phase 2b study in chronic spontaneous urticaria patients during the first half of 2025. We believe EVO756 is a potential treatment option for patients suffering from various mast-cell mediated diseases. https://lnkd.in/gzUGPVdq

Thank you to #NASDAQ for recognizing a new and exciting milestone. We are committed to making a difference for patients suffering from chronic inflammation. Adding this exciting new targeted molecule is another important growth step for Evommune.